CDM-NAG is a useful tool compound to deliver the siRNA.

AGPS-IN-2i is a novel inhibitor of alkylglyceronephosphate synthase (agps), specifically impairing epithelial to mesenchymal transition (emt) by modulating e-cadherin, snail and mmp2 expression levels.

JSD26 is a selective S-nitroso-coenzyme A reductase 2 (SCoR2; AKR1A1) inhibitor with Ki of 93 nM, 10-fold selectivity over AKR1B1.

SM-102 is an ionizable amino lipid that has been used in combination with other lipids in the formation of lipid nanoparticles.Administration of luciferase mRNA in SM-102-containing lipid nanoparticles induces hepatic luciferase expression in mice. Formulations containing SM-102 have been used in the development of lipid nanoparticles for delivery of mRNA-based vaccines.

VV261 is an orally active Influenza Virus inhibitor. VV261 has demonstrated activity against severe febrile thrombocytopenia syndrome virus (SFTSV) and lymphocytic choriomeningitis virus (LCMV) (EC50: 0.89 and 0.15, respectively).

Antabactin (ANT) is a highly potent pan-abscisic acid (ABA) receptor antagonist with EC50 of 760 nM and picomolar dissociation constant, disrupts signaling by preventing receptor-PP2C interactions.

MOCHOL​ is a novel, synthetically derived cholesterol analog designed as a lipid component in Lipid Nanoparticles (LNPs).

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM, respectively.

Zelavespib (PU-H71) is a potent Hsp90 inhibitor, with an IC50 of 51 nM in MDA-MB-468 cells.

PAR2 antagonist C391 (C391) is a selective PAR2 antagonist, potently inhibits peptidomimetic-induced PAR2 Ca2+ signalling with IC50 of 1.3 uM.C391 blocks both PAR2 Ca2+ and MAPK signalling pathways activated by peptidomimetics and/or proteinase activation.C391 effectively attenuated compound 48/80-induced thermal hyperalgesia in vivo.C391 blocked A. alternata-induced, PAR2-dependent Ca2+ and MAPK signalling in 16HBE14o- cells, as well as β-arrestin recruitment in HEK 293 cells.C391 effectively attenuated A. alternata-induced inflammation, mucus production, mucus cell hyperplasia and airway hyperresponsiveness in acute allergen-challenged murine models.

JNJ-74856665 is an orally bioavailable, potent, and selective DHODH inhibitor with IC50 of 0.40 nM. JNJ-74856665 shows favorable physicochemical properties and has been selected for clinical development in patients with AML and myelodysplastic syndromes (MDS).

DS03090629 is a potent, selective, ATP-competitive and orally available MEK1/2 inhibitor, shows high affinity for the MEK protein regardless of its phosphorylation status (npMEK (inactive) Kd=0.11 nM, and pMEK (active) Kd=0.15 nM).

Dizocilpine maleate(MK 801) is a potent N-methyl-D-aspartate (NMDA) receptor antagonist with Ki of 30.5 nM

CFTR Inhibitor II is a cell-permeable glycinyl hydrazone compound that acts as a potent, selective and reversible open-channel blocker of CFTR with intermediate speed (< 1 min; 95% inhibition at 50 µM; Ki = 4.3 µM in CFTR-expressing FRT cells.

Procyanidin B2 is a natural flavonoid, with anti-cancer, antioxidant activities.

AT-533 is a potent Hsp90 and HSV inhibitor. AT-533 suppresses tumor growth and angiogenesis by blocking the HIF-1α/VEGF/VEGFR-2 signaling pathway. AT-533 also inhibits the activation of the downstream pathways, including Akt/mTOR/p70S6K, Erk1/2 and FAK. AT-533 inhibits the tube formation, cell migration, and invasion of human umbilical vein endothelial cells (HUVECs).

(Rac)-Dizocilpine ((Rac)-MK-801) is the racemate of Dizocilpine (HY-15084B). Dizocilpine (MK-801), a potent anticonvulsant, is a selective and non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist.

Homoalanosine is a substance with herbicidal activity. Homoalanosine has the activity of removing a variety of weeds, but does not damage rice plants.

DDAO is a promising near-infrared (NIR) red fluorescent probe with tunable excitation wavelength (600-650 nm) and long emission wavelength (λem = 656 nm). DDAO can de desiged for detection of the activities of different enzymes such as β-galactosidase, sulfatase, protein phosphatase 2A, carboxylesterase 2, human albumin and esterases.

Hs-27 is a Novel Hsp90 Inhibitor, Exhibits Diagnostic and Therapeutic Potential in Triple Negative Breast Cancer.

AMPA receptor antagonist-3 is an AMPA receptor antagonist extracted from patent US20070027143A1. AMPA receptor antagonist-3 can be used for the research of central nervous system disorders.

A novel Non-competitive AMPA/kainate antagonist.

JNJ-7777120 is a selective H4R antagonist with Ki of 4 ±1 nM, exhibits >1000-fold selectivity over the other histamin receptors.

A novel Non-competitive AMPA/kainate antagonist.